Vaxxinity Past Earnings Performance
Past criteria checks 0/6
Vaxxinity's earnings have been declining at an average annual rate of -8.4%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 136.1% per year.
Key information
-8.4%
Earnings growth rate
9.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -136.1% |
| Return on equity | -424.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Vaxxinity makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -57 | 22 | 36 |
| 30 Sep 23 | 0 | -66 | 27 | 41 |
| 30 Jun 23 | 0 | -72 | 29 | 45 |
| 31 Mar 23 | 0 | -75 | 29 | 48 |
| 31 Dec 22 | 0 | -75 | 28 | 48 |
| 30 Sep 22 | 0 | -103 | 51 | 52 |
| 30 Jun 22 | 0 | -114 | 51 | 63 |
| 31 Mar 22 | 0 | -123 | 50 | 71 |
| 31 Dec 21 | 0 | -137 | 52 | 71 |
| 30 Sep 21 | 0 | -102 | 24 | 63 |
| 30 Jun 21 | 0 | -88 | 22 | 47 |
| 31 Mar 21 | 1 | -68 | 20 | 30 |
| 31 Dec 20 | 1 | -40 | 12 | 21 |
Quality Earnings: VAXX is currently unprofitable.
Growing Profit Margin: VAXX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VAXX is unprofitable, and losses have increased over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare VAXX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VAXX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: VAXX has a negative Return on Equity (-424.6%), as it is currently unprofitable.